Clinical Trial Update: Secukinumab Therapy for the Treatment of Moderate to Severe Plaque Psoriasis With Response Monitoring Using Optical Coherence Tomography (OCT). [Phase 4]

View source ↗

Summary

A Phase 4 trial evaluating secukinumab for moderate to severe plaque psoriasis with response monitoring via optical coherence tomography.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Psoriasis Vulgaris

Drugs mentioned

• Secukinumab (secukinumab)

Snippet

Sponsor: Narrows Institute for Biomedical Research | Conditions: Psoriasis Vulgaris | Phase 4 | Status: UNKNOWN